Runben Biotechnology Co., Ltd. (SHA:603193)
China · Delayed Price · Currency is CNY 20.77
+0.12 (0.58%)
Jun 18, 2026, 11:19 AM CST
Runben Biotechnology Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Runben Biotechnology stock has a consensus rating of "Strong Buy" and an average price target of ¥32.98. The average 1-year stock price forecast is 58.79% higher than the current stock price, while the lowest is ¥30.00 (+44.44%) and the highest is ¥36.40 (+75.25%).
Price Target: ¥32.98 (+58.79%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Runben Biotechnology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Jan '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 3 | 4 | 4 |
Financial Forecast
Revenue This Year
1.86B
from 1.54B
Increased by 20.28%
Revenue Next Year
2.19B
from 1.86B
Increased by 17.73%
EPS This Year
1.21
EPS Next Year
n/a
from 1.21
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.9B | ||
| Avg | 1.9B | ||
| Low | 1.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 20.7% | ||
| Avg | 20.3% | ||
| Low | 19.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.21 | ||
| Avg | 1.21 | ||
| Low | 1.21 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 70.4% | ||
| Avg | 70.4% | ||
| Low | 70.4% |